J&J Robotics Win, Lilly Obesity Pill Clear UK Hurdles

Eli Lilly ($LLY) shares rose 2.1% following UK regulatory clearance of Foundayo, the company's first oral obesity pill, extending its incretin portfolio beyond injectable medicines including Mounjaro and Zepbound. Analysts updated fair value estimates from $1,270.37 to $1,297.31, reflecting revisions tied to second-quarter results and the potential of the GLP-1 franchise, including retatrutide and Foundayo. Commentary from Jeff Marks and Jim Cramer suggested the stock rally driven by surging global demand for GLP-1 therapies has years left to run.

Johnson & Johnson ($JNJ) reported strong second-quarter 2026 results with sales growing nearly 7% to $25.31 billion, above the $25.05 billion analyst estimate, and adjusted earnings per share of $2.90 surpassing the $2.85 expectation. The company announced a $5.50 billion talc settlement framework and received FDA Priority Review for its RYBREVANT FASPRO oncology franchise. $JNJ also agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies alongside leadership changes in its Innovative Medicine unit and new MedTech partnerships.

Johnson & Johnson ($JNJ) received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, a milestone that positions the company to compete in the surgical robotics market. This clearance was part of a cluster of recent developments that also included strong second-quarter performance and advancement of its oncology and MedTech portfolios. Separately, Intuitive Surgical ($ISRG) beat both top- and bottom-line consensus estimates in fiscal second-quarter 2026 results, with revenue growing 19% to $2.89 billion and adjusted earnings per share of $2.80 exceeding expectations by $0.30. Despite the earnings beat, the stock declined due to mounting concerns about slowing domestic procedure growth for its da Vinci and Ion platforms.

Bristol Myers Squibb ($BMY) announced plans to build a $2.3 billion drug manufacturing campus in Houston, expected to create 500 jobs. The facility represents a significant capital commitment to expand domestic biologics production capacity. In the biotech M&A space, Lakefront Biotherapeutics completed its acquisition of Ouro Medicines with Gilead Sciences ($GILD) to advance a potential first and best-in-class T-cell engager. Lakefront forecast at least €1.6 billion of cash remaining after funding its portfolio to first gamgertamig approval and maintained year-end 2026 cash and financial investments balance guidance of approximately €2 billion, which now includes a €50 million share repurchase.

Arbutus Biopharma ($ABUS) reached a landmark legal settlement with Moderna ($MRNA) resolving global patent infringement litigation over lipid nanoparticle delivery technology. The resolution provided Arbutus with a non-dilutive liquidity boost while removing a significant overhang for both companies in the mRNA technology sector.

Thermo Fisher Scientific ($TMO) highlighted new FDA-cleared diagnostic platforms at the ADLM conference in Anaheim in late July 2026, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases. The company paired these regulatory milestones with integrated software such as LabLink360 and broad biomarker portfolios like B·R·A·H·M·S to strengthen its clinical laboratory offerings. A market report released today forecasts the global non-viral transfection reagents market will increase from $0.89 billion in 2026 to $2.01 billion by 2035, expanding at a compound annual growth rate of 9.5%, with $TMO among the featured players alongside Bio-Rad, MaxCyte, and MilliporeSigma.

Sen. Elizabeth Warren criticized vertical integration in the U.S. healthcare system, arguing it leads to higher costs for patients and increased profits for large corporations. Warren used UnitedHealth Group ($UNH) and CVS Health ($CVS) as examples, stating they have too much control over the healthcare system and calling for a breakup of vertical integration structures. The comments reflect ongoing political scrutiny of payer-provider consolidation and pharmacy benefit manager practices. Healthcare stocks traded higher late in the session, with the NYSE Healthcare Index rising 1%.

Investors will monitor execution on Johnson & Johnson's ($JNJ) OTTAVA commercial rollout and Eli Lilly's ($LLY) European launch strategy for Foundayo following UK approval. Bristol Myers Squibb's ($BMY) Houston manufacturing campus timeline and production ramp will be key for supply chain visibility. Broader sector focus remains on GLP-1 demand durability, managed care reform proposals, and procedure volume trends for surgical robotics platforms. Analysts noted that quarterly earnings growth for S&P 500 companies eased from a week ago amid a drop in the healthcare sector contribution, according to Oppenheimer.